Vascular Occlusion Mechanism: How Does It Occur?
Filler injection-related vascular occlusion develops through two different mechanisms:
- Intravascular injection (Direct mechanism): Filler material is injected directly into the lumen of a vessel. This occurs when the needle or cannula pierces through the vessel wall. Under pressure, filler can reverse blood flow and reach distant vascular beds including the retinal artery.
- External compression (Indirect mechanism): Filler placed in surrounding tissue externally compresses an adjacent vessel, cutting off blood flow. This type has a more insidious onset; symptoms may be delayed.
In both mechanisms the result is the same: cessation of oxygen and nutrients to the affected area — ischaemia — and if untreated, necrosis (tissue death).
High-Risk Zone Map
Some anatomical areas of the face carry much higher risk for vascular occlusion due to dense vascular networks and anastomotic structures:
| Area | Risk Level | Relevant Vessel(s) | Potential Complication |
|---|---|---|---|
| Glabella (between brows) | Highest | Supratrochlear, Supraorbital arteries | Forehead necrosis, vision loss |
| Nose (dorsum and tip) | Very High | Angular artery, Dorsal nasal artery | Nasal tip necrosis, alar loss |
| Nasolabial area | High | Angular artery, Facial artery | Cheek/lip necrosis |
| Forehead | High | Supratrochlear, Supraorbital arteries | Forehead necrosis, vision loss risk |
| Lips | Medium–High | Superior/inferior labial arteries | Lip necrosis |
| Temple (temporal) | Medium–High | Superficial temporal artery | Frontal necrosis, vision loss |
| Cheek–Malar | Moderate | Infraorbital artery, Zygomaticofacial | Local ischaemia |
| Under-eye (Tear trough) | High | Angular artery, Infraorbital artery | Vision loss risk |
Early Signs and Critical Timeline
The course of vascular occlusion is shaped within minutes. Time is critical:
| Time | Symptoms | Significance |
|---|---|---|
| Immediately (0–2 min) | Sudden, intense blanching — area turns chalk white | Sign of intravascular injection or acute compression — EMERGENCY |
| 2–15 min | Livedo reticularis (net-like purple-grey discolouration), severe pain | Ischaemia deepening — intervention window narrowing |
| 15–60 min | Bruising, swelling, heat loss in area, onset of bullae | Deep ischaemia — intervention may still be effective |
| 1–6 hours | Dark discolouration (blackening beginning), tissue loss risk | Necrosis onset — early intervention still important |
| 6–24 hours and beyond | Crusting, tissue death, scarring potential | Necrosis established — long-term management phase |
Clinical rule: The "first 60 minutes critical" principle absolutely applies to vascular occlusion. The earlier hyaluronidase is given, the higher the chance of reversal.
Hyaluronidase Emergency Protocol: Dose, Technique and Timing
Hyaluronidase is the only antidote that enzymatically dissolves hyaluronic acid filler. It must be used immediately on suspicion of vascular occlusion:
- Dose range: 150–1,500 IU (some protocols recommend above 1,500 IU; decision based on the clinic's available dose and severity of the case).
- Application technique: Multiple-point, wide-area injection spread across the vascular feeding territory of the affected vessel. Spreading across the area is recommended rather than delivering the entire dose at one point.
- Repeat dose: Response is assessed 30–60 minutes after the first application; if blanching continues, additional dose is applied. Can be repeated over 24 hours if necessary.
- Response criteria: Colour return (becoming pink), shortening of capillary refill time, decrease in pain. These changes are signs of improvement.
Warm Compress and Massage Protocol
Should be applied simultaneously with or immediately after hyaluronidase:
- Warm compress: Moist compress at 40–42°C (tolerable heat). Provides vasodilation increasing hyperaemia; helps filler dissolve.
- Massage: Gentle circular massage to the affected area — mechanically supports filler dissolution. Caution: if massage causes pain or touch sensation is lost (neuropathy), do not force.
- Nitrate cream (GTN): Glyceryl trinitrate cream is recommended in some protocols; provides vasodilatory effect.
- Aspirin 300 mg: Given for antiplatelet effect; helps prevent thrombus formation.
Vision Loss Risk: Orbital Spread and Emergency Management
The most devastating complication of vascular occlusion is vision loss developing when filler reaches the retinal or ophthalmic artery. This is a serious medical emergency:
In glabella, nasal dorsum and forehead injections, filler can reach the retinal artery retrogradely via the ophthalmic artery. This is called "retrograde embolisation" and leads to central retinal artery occlusion.
Signs of orbital spread:
- Sudden blurring or loss of vision (unilateral)
- Eye pain
- Ophthalmoplegia (restricted eye movement)
- Ptosis (eyelid drooping)
What to do with these signs:
- Call emergency services immediately.
- Intraorbital hyaluronidase injection may be considered by an experienced physician (controversial; requires specialist opinion).
- Systemic heparin and ophthalmology consultation.
- Patient laid flat; head kept in a neutral position.
Critical note: In vision loss cases, the first 90 minutes (retinal ischaemia tolerance window) is considered the intervention window. Therefore emergency services should be called without delay.
24 / 48 / 72 Hour Follow-Up Protocol
| Time | Assessment | Possible Intervention |
|---|---|---|
| 0–6 hours (Clinic) | Colour, capillary refill, pain, vision check | Additional hyaluronidase, repeat warm compress |
| 24 hours | Necrosis development, bullae, pain level | Initiating wound care, antibiotic assessment |
| 48 hours | Tissue healing response, signs of infection | Antimicrobial therapy if needed |
| 72 hours | Necrosis border clarifying, scar formation beginning | Plastic surgery or wound specialist consultation |
| 2–4 weeks | Scar assessment, PIH monitoring | Scar treatment planning (silicone gel, laser) |
Long-Term Scar Management
Long-term management is needed for necrotic areas developing after vascular occlusion:
- Wound healing phase (0–4 weeks): Occlusive dressings, moist wound environment, infection prophylaxis.
- Scar maturation phase (1–12 months): Silicone gel/sheet application, sun protection, massage.
- Scar treatment: Fractional laser or microneedling for atrophic scars; intralesional triamcinolone for hypertrophic scars.
- Pigmentation management: Protocols containing kojic acid, niacinamide, tranexamic acid for post-inflammatory hyperpigmentation.
Application Techniques That Reduce Vascular Occlusion Risk
It is not possible to prevent all vascular complications; however, risk can be significantly reduced with the following techniques:
- Increased cannula preference: Use of blunt-tipped cannulas especially in the glabella, nose and under-eye areas significantly reduces the risk of vessel perforation.
- Aspiration test: Gentle aspiration before each injection; if blood returns, withdraw and reposition the needle.
- Low pressure, slow injection: High pressure increases the risk of retrograde embolisation.
- Small aliquots: Small amounts at multiple points rather than large volume at a single point.
- Anatomical knowledge: It is essential to know the vascular anatomy and variations of the area before injection.
Frequently Asked Questions
I had filler and have bruising and swelling in the area. Is this vascular occlusion? The difference from normal bruising and swelling is this: occlusion begins with blanching or livedo (net-like purple-grey colour) + severe pain. Ordinary bruising is typically blue-purple in colour, generally painless or mildly tender. If in doubt, call your clinic immediately.
Is hyaluronidase available at every clinic? It should be. Every clinic performing filler must have hyaluronidase as mandatory emergency equipment. You can ask your clinic this question before the procedure.
Can vision loss be permanent? Yes, with delayed intervention permanent vision loss can develop. For this reason, emergency services must be called immediately when visual symptoms appear, and no minutes should be wasted.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.